Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | SNCA | P37840 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21061557 | 0.90 | PDGFRB (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL30434988 | 0.90 | PDGFRB (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL27719772 | 0.88 | PDGFRB (0.56) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL25314269 | 0.86 | CHEK1 (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL10473975 | 0.86 | MAPT (0.50) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL29805390 | 0.85 | MTNR1A (0.46) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL7210732 | 0.84 | PDGFRB (0.60) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL30435368 | 0.83 | ALDH1A1 (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL3010413 | 0.83 | ATM (0.51) | SNCAATMTDP1ALDH1A1MAPT | |
| SCHEMBL23861174 | 0.82 | PDGFRB (0.56) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-12391727-B2 | Traceless reductively cleavable linker molecules for peptide purification | Gyros Protein Technologies AB (SE) | 2025-08-19 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| US-12269845-B2 | Traceless reductively cleavable linker molecules for peptide purification | Gyros Protein Technologies AB (SE) | 2025-04-08 | — | — | US | disclosed |
| US-20240116981-A1 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | Belyntic GmbH (DE) | 2024-04-11 | — | — | US | disclosed |
| CN-112638864-B | Traceless reductive cleavable linker molecules for peptide purification | 格瑞罗斯普罗泰恩科技公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| EP-4219446-A2 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | Gyros Protein Technologies AB (SE) | 2023-08-02 | — | — | EP | disclosed |
| CN-112079764-B | Synthesis method of sunitinib intermediate 5-fluoroindol-2-one | 山东汇海医药化工有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20210332082-A1 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | Belyntic GmbH (DE) | 2021-10-28 | — | — | US | disclosed |
| WO-2009127822-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2009-10-22 | — | — | WO | disclosed |
| US-7342040-B2 | 5-fluorooxindole-3-carboxylic acid ester | UBE INDUSTRIES, LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050182123-A1 | 5-Fluorooxindole-3-carboxylic acid ester | UBE INDUSTRIES, LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-6900335-B2 | Process for producing 5-fluorooxindole and for producing intermediates therefor | UBE INDUSTRIES, LTD. (JP) | 2005-05-31 | — | — | US | disclosed |
| US-20030181731-A1 | Process for producing 5-fluorooxyindole and for producing intermediates therefor | UBE INDUSTRIES., LTD (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| EP-1310486-A1 | PROCESS FOR PRODUCING 5-FLUOROOXYINDOLE AND FOR PRODUCING INTERMEDIATE THEREFOR | Ube Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391727-B2 | Traceless reductively cleavable linker molecules for peptide purification | VIP, NGLY1, HM13 | PDGFRB 3739/4885FGFR1 1674/4885PDGFRA 4084/4885 |
| US-20210332082-A1 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | VIP, NGLY1, HM13 | PDGFRB 3739/4885FGFR1 1674/4885PDGFRA 4084/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | PDGFRB 3850/4885FGFR1 3798/4885PDGFRA 3505/4885 |
| US-12269845-B2 | Traceless reductively cleavable linker molecules for peptide purification | VIP, NGLY1, HM13 | PDGFRB 3739/4885FGFR1 1674/4885PDGFRA 4084/4885 |
| US-20050182123-A1 | 5-Fluorooxindole-3-carboxylic acid ester | CYP4F2, AKR7A2, CYP2F1 | PDGFRB 2461/4885FGFR1 1509/4885PDGFRA 1770/4885 |
| US-20240116981-A1 | TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES FOR PEPTIDE PURIFICATION | VIP, NGLY1, HM13 | PDGFRB 3843/4885FGFR1 1565/4885PDGFRA 4400/4885 |
| US-20030181731-A1 | Process for producing 5-fluorooxyindole and for producing intermediates therefor | FAR1, CYP4F11, FDPS | PDGFRB 4352/4885FGFR1 887/4885PDGFRA 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.